245 related articles for article (PubMed ID: 16918323)
1. Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives.
Fusi F; Saponara S; Valoti M; Dragoni S; D'Elia P; Sgaragli T; Alderighi D; Kawase M; Shah A; Motohashi N; Sgaragli G
Curr Drug Targets; 2006 Aug; 7(8):949-59. PubMed ID: 16918323
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
3. 5-Oxo-hexahydroquinoline Derivatives and Their Tetrahydroquinoline Counterparts as Multidrug Resistance Reversal Agents.
Shahraki O; Khoshneviszadeh M; Dehghani M; Mohabbati M; Tavakkoli M; Saso L; Edraki N; Firuzi O
Molecules; 2020 Apr; 25(8):. PubMed ID: 32316291
[TBL] [Abstract][Full Text] [Related]
4. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
Mohammad IS; He W; Yin L
Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043
[TBL] [Abstract][Full Text] [Related]
5. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
7. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S
Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
[TBL] [Abstract][Full Text] [Related]
8. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
9. Marine Natural Products as Models to Circumvent Multidrug Resistance.
Long S; Sousa E; Kijjoa A; Pinto MM
Molecules; 2016 Jul; 21(7):. PubMed ID: 27399665
[TBL] [Abstract][Full Text] [Related]
10. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
12. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
Zhang Q; Li F
Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
[TBL] [Abstract][Full Text] [Related]
13. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
Xue X; Liang XJ
Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
[TBL] [Abstract][Full Text] [Related]
14. Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells.
Guberović I; Marjanović M; Mioč M; Ester K; Martin-Kleiner I; Šumanovac Ramljak T; Mlinarić-Majerski K; Kralj M
Sci Rep; 2018 Sep; 8(1):14467. PubMed ID: 30262858
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Traditional Chinese Medicine on P-Glycoprotein-Mediated Multidrug Resistance and Approaches for Studying the Herb-P-Glycoprotein Interactions.
Cao Y; Shi Y; Cai Y; Hong Z; Chai Y
Drug Metab Dispos; 2020 Oct; 48(10):972-979. PubMed ID: 32816867
[TBL] [Abstract][Full Text] [Related]
16. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells.
Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R
Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037
[TBL] [Abstract][Full Text] [Related]
19. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S; Gualtieri F
Curr Drug Targets; 2006 Jul; 7(7):893-909. PubMed ID: 16842220
[TBL] [Abstract][Full Text] [Related]
20. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp).
Zhang H; Xu H; Ashby CR; Assaraf YG; Chen ZS; Liu HM
Med Res Rev; 2021 Jan; 41(1):525-555. PubMed ID: 33047304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
